Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- 15 Dec 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
- 21 Jan 2008 Biomarkers information updated
- 29 Nov 2007 Status changed from recruiting to completed.